Avantogen Oncology Inc. Announces FDA Acceptance Of Its IND For The Novel Cancer Drug Candidate, RP101 (RedNova)
Avantogen Oncology, Inc. (OTCBB:AVTO) today announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug Application (IND) for RP101, a compound being investigated for the treatment of patients with pancreatic cancer.

Current FDA Environment a key topic of Wall Street Transcript Biotechnology Issue (Wall Street Transcript via Yahoo! Finance)
67 WALL STREET, New York--October 30, 2006--The Wall Street Transcript has just published its Biotechnology issue, a report offering a timely review of the sector to serious investors and industry executives. This 86-page feature contains an expert roundtable forum of leading industry analysts, and industry commentary through in-depth interviews with top management from 19 firms. The issue also

Sonus Pharmaceuticals to Release Third Quarter Financial Results and Hold Quarterly Conference Call November 8 (RedNova)
Sonus Pharmaceuticals, Inc. (NASDAQ:SNUS) will release third quarter financial results on Wednesday, November 8, after the close of market. At 4:30 P.M. ET, management will host a conference call to provide a company update. The conference call will be web cast live at 1:30 P.M.